{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T23:12:03Z","timestamp":1790291523895,"version":"4.1.0"},"reference-count":44,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T00:00:00Z","timestamp":1747699200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p>Ferroptosis, an iron-dependent form of regulated cell death (RCD), has been proven to affect the response to antineoplastic therapies. However, little is known about the role of ferroptosis in chemotherapy and immune checkpoint inhibitor (ICI) therapy responses, as well as the molecular subtype identification of triple-negative breast cancer (TNBC).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We performed unsupervised clustering to stratify patients with TNBC in the Fudan University Shanghai Cancer Center (FUSCC) TNBC cohort into distinct ferroptosis-related subtypes according to the expression of eight ferroptosis-related genes (FRGs): EMC2, FTH1, HMOX1, LPCAT3, NOX4, SOCS1, BAP1, and ISCU. We conducted Gene Ontology (GO) analysis and gene set variation analysis (GSVA) to characterize the immune phenotype and enriched pathways of the distinct subtypes of TNBC. We constructed the FerrScore model to identify the most promising candidate compounds and predict ICI therapy benefits for patients with TNBC.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We identified two distinct ferroptosis-related subtypes with different overall survival (OS). Patients in cluster 1 exhibited better OS, which had a phenotype of a \u201chot\u201d tumor with abundant immune cell infiltration and higher expression of immune checkpoints compared to cluster 2. We screened everolimus as the most promising candidate drug for patients with high FerrScore referring to comprehensive factors including CMap score, experimental evidence, and clinical trial status. Further, we confirmed that FerrScore was a potentially powerful metric to predict anti-PD-L1, anti-PD-1, and anti-PD-1 + CTLA-4 ICI therapy benefits.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Ferroptosis reprogrammed the tumor microenvironment (TME) and classified patients into distinct subgroups with significantly different OS. FerrScore was a potentially powerful metric to screen candidate compounds and predict ICI therapy benefits for patients with TNBC, which prioritized clinical treatment strategies.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2025.1541119","type":"journal-article","created":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T09:59:25Z","timestamp":1747735165000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Ferroptosis-related gene signature-based subtype identification of triple-negative breast cancer to prioritize treatment strategies"],"prefix":"10.3389","volume":"15","author":[{"given":"Yongzhen","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoying","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junqi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanan","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuqian","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guozhong","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"You","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,5,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00693","article-title":"Validation of the DNA damage immune response signature in patients with triple-negative breast cancer from the swog 9313c trial","volume":"37","author":"Sharma","year":"2019","journal-title":"J Clin Oncol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/j.cell.2018.03.041","article-title":"Chemoresistance evolution in triple-negative breast cancer delineated by single-cell sequencing","volume":"173","author":"Kim","year":"2018","journal-title":"Cell"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.71.3495","article-title":"Enzalutamide for the treatment of androgen receptor-expressing triple-negative breast cancer","volume":"36","author":"Traina","year":"2018","journal-title":"J Clin Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0000000000002373","article-title":"Tumor biology and response to chemotherapy impact breast cancer-specific survival in node-positive breast cancer patients treated with neoadjuvant chemotherapy: long-term follow-up from acosog Z1071 (Alliance)","volume":"266","author":"Boughey","year":"2017","journal-title":"Ann Surg"},{"key":"B6","doi-asserted-by":"publisher","first-page":"4265","DOI":"10.1038\/s41467-020-18042-2","article-title":"Advances and challenges in retinoid delivery systems in regenerative and therapeutic medicine","volume":"11","author":"Ferreira","year":"2020","journal-title":"Nat Commun"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2023.110774","article-title":"Crosstalk between regulated cell death and immunity in redox dyshomeostasis for pancreatic cancer","volume":"109","author":"Zhou","year":"2023","journal-title":"Cell signalling"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1007\/s13402-023-00912-8","article-title":"Omics-based molecular classifications empowering in precision oncology","volume":"47","author":"Zhou","year":"2024","journal-title":"Cell Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4418","article-title":"Cytoplasmic P53 couples oncogene-driven glucose metabolism to apoptosis and is a therapeutic target in glioblastoma","volume":"23","author":"Mai","year":"2017","journal-title":"Nat Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1172\/JCI45014","article-title":"Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies","volume":"121","author":"Lehmann","year":"2011","journal-title":"J Clin Invest"},{"key":"B11","doi-asserted-by":"publisher","first-page":"e0157368","DOI":"10.1371\/journal.pone.0157368","article-title":"Refinement of triple-negative breast cancer molecular subtypes: implications for neoadjuvant chemotherapy selection","volume":"11","author":"Lehmann","year":"2016","journal-title":"PloS One"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-14-0673","article-title":"Phosphatase ptp4a3 promotes triple-negative breast cancer growth and predicts poor patient survival","volume":"76","author":"den Hollander","year":"2016","journal-title":"Cancer Res"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-0432","article-title":"Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer","volume":"21","author":"Burstein","year":"2015","journal-title":"Clin Cancer Res"},{"key":"B14","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.ccell.2019.02.001","article-title":"Genomic and transcriptomic landscape of triple-negative breast cancers: subtypes and treatment strategies","volume":"35","author":"Jiang","year":"2019","journal-title":"Cancer Cell"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/s41422-022-00614-0","article-title":"Comprehensive metabolomics expands precision medicine for triple-negative breast cancer","volume":"32","author":"Xiao","year":"2022","journal-title":"Cell Res"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-020-00462-0","article-title":"Broadening horizons: the role of ferroptosis in cancer","volume":"18","author":"Chen","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/s41557-020-0513-5","article-title":"Cd44 regulates epigenetic plasticity by mediating iron endocytosis","volume":"12","author":"Muller","year":"2020","journal-title":"Nat Chem"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/nchembio.2239","article-title":"Acsl4 dictates ferroptosis sensitivity by shaping cellular lipid composition","volume":"13","author":"Doll","year":"2017","journal-title":"Nat Chem Biol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aba8968","article-title":"Synthetic lethal combination targeting bet uncovered intrinsic susceptibility of tnbc to ferroptosis","volume":"6","author":"Verma","year":"2020","journal-title":"Sci Adv"},{"key":"B20","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.cmet.2022.09.021","article-title":"Ferroptosis heterogeneity in triple-negative breast cancer reveals an innovative immunotherapy combination strategy","volume":"35","author":"Yang","year":"2023","journal-title":"Cell Metab"},{"key":"B21","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1007\/s10549-024-07387-7","article-title":"Ferroptosis as a promising targeted therapy for triple negative breast cancer","volume":"207","author":"Mokhtarpour","year":"2024","journal-title":"Breast Cancer Res Treat"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101915","article-title":"Dual ferroptosis induction in N2-tans and tnbc cells via fth1 targeting: A therapeutic strategy for triple-negative breast cancer","volume":"6","author":"Liu","year":"2025","journal-title":"Cell Rep Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-065X.2012.01146.x","article-title":"Pamps and damps: signal 0s that spur autophagy and immunity","volume":"249","author":"Tang","year":"2012","journal-title":"Immunol Rev"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1021\/acsnano.2c01619","article-title":"Carbon quantum dots-based nanozyme from coffee induces cancer cell ferroptosis to activate antitumor immunity","volume":"16","author":"Yao","year":"2022","journal-title":"ACS Nano"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1093\/bib\/bbab388","article-title":"Ferroptosis-related lncrna pairs to predict the clinical outcome and molecular characteristics of pancreatic ductal adenocarcinoma","volume":"23","author":"Tang","year":"2022","journal-title":"Brief Bioinform"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2021.1959977","article-title":"Molecular subtypes based on ferroptosis-related genes and tumor microenvironment infiltration characterization in lung adenocarcinoma","volume":"10","author":"Zhang","year":"2021","journal-title":"Oncoimmunology"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.45050","article-title":"A novel ferroptosis-related gene signature for overall survival prediction in patients with hepatocellular carcinoma","volume":"16","author":"Liang","year":"2020","journal-title":"Int J Biol Sci"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1172\/JCI91190","article-title":"Ifn-gamma-related mrna profile predicts clinical response to pd-1 blockade","volume":"127","author":"Ayers","year":"2017","journal-title":"J Clin Invest"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.98368","article-title":"Efficacy of intracellular immune checkpoint-silenced dc vaccine","volume":"3","author":"Wang","year":"2018","journal-title":"JCI Insight"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1170-y","article-title":"Cd8(+) T cells regulate tumour ferroptosis during cancer immunotherapy","volume":"569","author":"Wang","year":"2019","journal-title":"Nature"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/nature23007","article-title":"Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway","volume":"547","author":"Viswanathan","year":"2017","journal-title":"Nature"},{"key":"B32","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.canlet.2016.07.035","article-title":"Induction of ferroptotic cell death for overcoming cisplatin resistance of head and neck cancer","volume":"381","author":"Roh","year":"2016","journal-title":"Cancer Lett"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2020.10.001","article-title":"The challenges of tumor mutational burden as an immunotherapy biomarker","volume":"39","author":"Jardim","year":"2021","journal-title":"Cancer Cell"},{"key":"B34","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1038\/s41418-018-0173-9","article-title":"Ferroptosis and necroinflammation, a yet poorly explored link","volume":"26","author":"Proneth","year":"2019","journal-title":"Cell Death Differ"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/ni.3775","article-title":"Tissue-resident memory features are linked to the magnitude of cytotoxic T cell responses in human lung cancer","volume":"18","author":"Ganesan","year":"2017","journal-title":"Nat Immunol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djab121","article-title":"Determining pd-L1 status in patients with triple-negative breast cancer: lessons learned from impassion130","volume":"114","author":"Badve","year":"2022","journal-title":"J Natl Cancer Institute"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1172\/JCI16156","article-title":"Suppressor of cytokine signaling-1 regulates acute inflammatory arthritis and T cell activation","volume":"111","author":"Egan","year":"2003","journal-title":"J Clin Invest"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/bgad060","article-title":"Socs1 acts as a ferroptosis driver to inhibit the progression and chemotherapy resistance of triple-negative breast cancer","volume":"44","author":"Wang","year":"2023","journal-title":"Carcinogenesis"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1002\/iub.1728","article-title":"Socs1 is associated with clinical progression and acts as an oncogenic role in triple-negative breast cancer","volume":"70","author":"Qian","year":"2018","journal-title":"IUBMB Life"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/j.cell.2018.09.022","article-title":"Protein barcodes enable high-dimensional single-cell crispr screens","volume":"175","author":"Wroblewska","year":"2018","journal-title":"Cell"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abe8219","article-title":"In vivo genome-wide crispr screens identify socs1 as intrinsic checkpoint of cd4(+) th1 cell response","volume":"6","author":"Sutra Del Galy","year":"2021","journal-title":"Sci Immunol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"e2200978","DOI":"10.1002\/advs.202200978","article-title":"Multiomics analysis identifies socs1 as restraining T cell activation and preventing graft-versus-host disease","volume":"9","author":"Guo","year":"2022","journal-title":"Adv Sci (Weinh)"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-19-3158","article-title":"Nox4 inhibition potentiates immunotherapy by overcoming cancer-associated fibroblast-mediated cd8 T-cell exclusion from tumors","volume":"80","author":"Ford","year":"2020","journal-title":"Cancer Res"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2023.111008","article-title":"Nox4 alleviates breast cancer cell aggressiveness by co-ordinating mitochondrial turnover through pgc1alpha\/drp1 axis","volume":"115","author":"Bhadane","year":"2024","journal-title":"Cell signalling"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1541119\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T09:59:26Z","timestamp":1747735166000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1541119\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,20]]},"references-count":44,"alternative-id":["10.3389\/fonc.2025.1541119"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1541119","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,20]]},"article-number":"1541119"}}